Table 1.

Research variables.

Categories	Variables	Specific indicators	Definition
Basic information	Indication	/	/
	Tumor type
	Marketing time
	Medical insurance access time
Trial design characteristics	Primary endpoint	Only OS	Only taking one of OS, PFS and ORR as primary endpoint
		Only PFS
		Only ORR
		Other	Not taking any of the endpoints of OS, PFS, ORR as primary endpoint
		Two endpoints	Two endpoints in OS, PFS, and ORR are used simultaneously as primary endpoints
	Phase	Phase I	Phase of the pivotal clinical trials included in this study
		Phase II
		Phase III
	Blinded trial	Yes/No	Whether the pivotal clinical trials included in the study were blinded
	Control group	Yes/No	Whether the pivotal clinical trials included in the study had a control group
	Randomization	Yes/No	Whether the pivotal clinical trials included in the study were randomized
Clinical outcomes	Risk benefit	HROS data available (Yes/No)	Whether HROS, HRPFS data of the drug are provided
		HRPFS data available(Yes/No)
		Risk benefit in OS (Yes/No)	“Benefit” means an HR of < 1. “No benefit” refers to HR ≥ 1 or P ≥ 0.05 Risk benefit = (1-HR)100%
		Risk benefit in PFS (Yes/No)
		Magnitude of RiskOS benefit	Comparing HR values for drugs with risk-benefit, the smaller the HR, the greater the risk of disease progression or death reduced by the drug, and the greater the risk benefit.
		Magnitude of RiskPFS benefit
	Survival benefit	Survival benefit for mOS	The difference in median survival time between the experimental and control groups
		Survival benefit for mPFS
	Reimbursement decisions	Positive /negative	Whether the drug indications are included in the NRDL (2021 edition)